UBS has given Carl Zeiss Meditec a "Neutral" rating and a price target of 65 euros after the company's fourth-quarter figures were released.
The current share price is 49.16 euros, which is a decrease of 2.74 euros or 5.28%. Analyst Graham Doyle mentioned that the operating profit target for 2025 is expected to be more than 10% lower than what the market expects.
Concerns about a weak economy and reduced consumer spending in China are likely to have a negative impact on investor sentiment towards the company's shares.